KR100705525B1 - 치환되고 분지화된3-아미노-1-페닐-1ｈ-〔1,2,4〕트리아졸의 신규한 아미노유도체, 이의 제조 방법, 및 이를 포함하는 제약 조성물 - Google Patents

치환되고 분지화된3-아미노-1-페닐-1ｈ-〔1,2,4〕트리아졸의 신규한 아미노유도체, 이의 제조 방법, 및 이를 포함하는 제약 조성물 Download PDF

Info

Publication number
KR100705525B1
KR100705525B1 KR1020027007736A KR20027007736A KR100705525B1 KR 100705525 B1 KR100705525 B1 KR 100705525B1 KR 1020027007736 A KR1020027007736 A KR 1020027007736A KR 20027007736 A KR20027007736 A KR 20027007736A KR 100705525 B1 KR100705525 B1 KR 100705525B1
Authority
KR
South Korea
Prior art keywords
cyclopropyl
alkyl
propyl
methylphenyl
amine hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027007736A
Other languages
English (en)
Korean (ko)
Other versions
KR20020061002A (ko
Inventor
미첼 게슬링
다니엘 굴리
장-삐에르 마프란드
삐에르 로저
Original Assignee
사노피-아벤티스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 filed Critical 사노피-아벤티스
Publication of KR20020061002A publication Critical patent/KR20020061002A/ko
Application granted granted Critical
Publication of KR100705525B1 publication Critical patent/KR100705525B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020027007736A 1999-12-17 2000-12-14 치환되고 분지화된3-아미노-1-페닐-1ｈ-〔1,2,4〕트리아졸의 신규한 아미노유도체, 이의 제조 방법, 및 이를 포함하는 제약 조성물 Expired - Fee Related KR100705525B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9915935A FR2802530B1 (fr) 1999-12-17 1999-12-17 Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
FR99/15935 1999-12-17

Publications (2)

Publication Number Publication Date
KR20020061002A KR20020061002A (ko) 2002-07-19
KR100705525B1 true KR100705525B1 (ko) 2007-04-10

Family

ID=9553380

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027007736A Expired - Fee Related KR100705525B1 (ko) 1999-12-17 2000-12-14 치환되고 분지화된3-아미노-1-페닐-1ｈ-〔1,2,4〕트리아졸의 신규한 아미노유도체, 이의 제조 방법, 및 이를 포함하는 제약 조성물

Country Status (33)

Country Link
US (1) US6806282B2 (https=)
EP (1) EP1242389B1 (https=)
JP (1) JP4146641B2 (https=)
KR (1) KR100705525B1 (https=)
CN (1) CN1293061C (https=)
AR (1) AR031837A1 (https=)
AT (1) ATE264847T1 (https=)
AU (1) AU780711B2 (https=)
BR (1) BR0017023A (https=)
CA (1) CA2398772C (https=)
CO (1) CO5251379A1 (https=)
CZ (1) CZ302460B6 (https=)
DE (1) DE60010126T2 (https=)
DK (1) DK1242389T3 (https=)
EA (1) EA004957B1 (https=)
EE (1) EE04778B1 (https=)
ES (1) ES2219436T3 (https=)
FR (1) FR2802530B1 (https=)
HU (1) HUP0204080A3 (https=)
IL (2) IL150037A0 (https=)
IS (1) IS2315B (https=)
ME (1) MEP12108A (https=)
MX (1) MXPA02006033A (https=)
NO (1) NO20022828L (https=)
PL (1) PL203819B1 (https=)
PT (1) PT1242389E (https=)
RS (1) RS50289B (https=)
SK (1) SK285994B6 (https=)
TR (2) TR200201600T2 (https=)
TW (1) TWI289554B (https=)
UA (1) UA73333C2 (https=)
WO (1) WO2001044207A2 (https=)
ZA (1) ZA200204422B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013982A1 (en) * 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
CA2697974C (en) 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
WO2009115547A1 (en) 2008-03-19 2009-09-24 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoiies as nicotinic acetylcholine receptor modulators
AR071763A1 (es) 2008-05-09 2010-07-14 Janssen Pharmaceutica Nv Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
EP2629616A4 (en) * 2010-10-21 2014-03-26 Merck Sharp & Dohme SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
RS65839B1 (sr) 2014-01-21 2024-09-30 Neurocrine Biosciences Inc Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
CN104059027B (zh) * 2014-07-01 2015-10-28 河北大学 一类含1,2,4-三唑的(e)-甲氧基亚氨基苯乙酸甲酯类化合物及其制备方法和用途
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MX2022002881A (es) * 2019-09-25 2022-06-08 Oncoarendi Therapeutics Sa Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039400A1 (en) * 1995-06-06 1996-12-12 Neurocrine Biosciences, Inc. Amino-substituted thiadiazoles, pyrimidines, triazines or triazoles useful as ctf receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3869167D1 (de) * 1987-03-27 1992-04-23 Kumiai Chemical Industry Co Phenyltriazol-derivate und insectizid.
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039400A1 (en) * 1995-06-06 1996-12-12 Neurocrine Biosciences, Inc. Amino-substituted thiadiazoles, pyrimidines, triazines or triazoles useful as ctf receptor antagonists

Also Published As

Publication number Publication date
TR200401775T4 (tr) 2004-09-21
CZ302460B6 (cs) 2011-06-01
EE04778B1 (et) 2007-02-15
JP4146641B2 (ja) 2008-09-10
PL203819B1 (pl) 2009-11-30
JP2003516975A (ja) 2003-05-20
US20030162771A1 (en) 2003-08-28
CN1434808A (zh) 2003-08-06
AU2525901A (en) 2001-06-25
HUP0204080A3 (en) 2005-01-28
PT1242389E (pt) 2004-08-31
EE200200331A (et) 2003-06-16
TWI289554B (en) 2007-11-11
BR0017023A (pt) 2002-12-03
CA2398772C (fr) 2011-07-05
KR20020061002A (ko) 2002-07-19
UA73333C2 (en) 2005-07-15
NO20022828L (no) 2002-08-19
AR031837A1 (es) 2003-10-08
FR2802530B1 (fr) 2002-02-22
ES2219436T3 (es) 2004-12-01
DE60010126T2 (de) 2005-04-28
WO2001044207B1 (fr) 2002-06-06
EA004957B1 (ru) 2004-10-28
EP1242389B1 (fr) 2004-04-21
MXPA02006033A (es) 2003-01-28
US6806282B2 (en) 2004-10-19
SK8502002A3 (en) 2003-02-04
IL150037A (en) 2007-02-11
IS2315B (is) 2007-11-15
SK285994B6 (sk) 2008-01-07
WO2001044207A8 (fr) 2001-07-12
HUP0204080A2 (hu) 2003-04-28
FR2802530A1 (fr) 2001-06-22
YU43902A (sh) 2005-03-15
MEP12108A (en) 2010-06-10
IS6402A (is) 2002-05-28
IL150037A0 (en) 2002-12-01
TR200201600T2 (tr) 2002-10-21
ATE264847T1 (de) 2004-05-15
DK1242389T3 (da) 2004-08-09
WO2001044207A3 (fr) 2001-12-20
AU780711B2 (en) 2005-04-14
NO20022828D0 (no) 2002-06-13
EP1242389A2 (fr) 2002-09-25
CA2398772A1 (fr) 2001-06-21
WO2001044207A2 (fr) 2001-06-21
DE60010126D1 (de) 2004-05-27
ZA200204422B (en) 2003-11-26
CN1293061C (zh) 2007-01-03
CO5251379A1 (es) 2003-02-28
HK1055947A1 (en) 2004-01-30
PL355811A1 (en) 2004-05-17
RS50289B (sr) 2009-09-08
EA200200523A1 (ru) 2002-12-26
CZ20022099A3 (cs) 2002-09-11

Similar Documents

Publication Publication Date Title
TWI415845B (zh) 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
PT1024138E (pt) Derivados de pirazole
KR100705525B1 (ko) 치환되고 분지화된3-아미노-1-페닐-1ｈ-〔1,2,4〕트리아졸의 신규한 아미노유도체, 이의 제조 방법, 및 이를 포함하는 제약 조성물
JP3290998B2 (ja) アミノチアゾール誘導体、その製造方法およびそれを含有してなる医薬組成物
JP2013545740A (ja) バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
BG65193B1 (bg) Производно на пиразолкарбоксилна киселина, неговото използване и фармацевтични състави, които го съдържат
EP0833822A1 (fr) Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
JP2001502712A (ja) 束縛されたソマトスタチン・アゴニスト及びアンタゴニスト
JP2013534229A (ja) バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体
JP2003505380A (ja) 新規アミノチアゾール誘導体、それらの製造およびそれらを含有する医薬組成物
US20040029875A1 (en) Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same
TW200916442A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20130321

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20140320

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160404

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160404

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000